{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T17:32:36Z","timestamp":1773509556108,"version":"3.50.1"},"reference-count":33,"publisher":"Scientific Scholar","issue":"03","license":[{"start":{"date-parts":[[2020,2,19]],"date-time":"2020-02-19T00:00:00Z","timestamp":1582070400000},"content-version":"vor","delay-in-days":598,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Lab Physicians"],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>\n          INTRODUCTION: Rosuvastatin is a lipid-lowering agent that inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase leading to a reduction of cholesterol biosynthesis. Many studies have shown an association between statins use and the reduction of sepsis. The aim of the present study was to evaluate the in vitro combined antibacterial activity of rosuvastatin and cefixime.<\/jats:p><jats:p>\n          MATERIALS AND METHODS: Five pathogenic bacteria isolates (Gram positive and Gram negative) were used for testing the antibacterial activity of rosuvastatin alone and in combination with cefixime.<\/jats:p><jats:p>\n          Results: Rosuvastatin mainly inhibited Klebsiella pneumoniae and Escherichia coli where it caused zones of inhibition of (17.9 \u00b1 0.6 mm) and (16.9 \u00b1 0.3 mm), respectively; however, it moderately inhibited the growth of Staphylococcus epidermidis (12.9 \u00b1 0.2 mm) and Staphylococcus aureus (12.76 \u00b1 0.2) and produced less inhibition for Pseudomonas aeruginosa growth where it led to a zone of inhibition equal to (9.1 \u00b1 0.5 mm). Minimal inhibitory concentration (\u03bcg\/mL) of rosuvastatin was high compared to cefixime. Fractional inhibitory concentration (FIC) of rosuvastatin was low for E. coli and K. pneumoniae compared to the other types of bacterial strains. Rosuvastatin exhibited additive effects with cefixime against E. coli and K. pneumoniae. \u03a3FIC index was 0.536 and 0.734 for E. coli and K. pneumoniae, respectively.<\/jats:p><jats:p>\n          Conclusions: Rosuvastatin has a significant antibacterial activity against both Gram-negative and Gram-positive bacteria with a potential additive effect when used in combination with cefixime.<\/jats:p>","DOI":"10.4103\/jlp.jlp_170_17","type":"journal-article","created":{"date-parts":[[2018,7,6]],"date-time":"2018-07-06T05:03:48Z","timestamp":1530853428000},"page":"271-275","source":"Crossref","is-referenced-by-count":16,"title":["Rosuvastatin as forthcoming antibiotic or as adjuvant additive agent: In vitro novel antibacterial study"],"prefix":"10.25259","volume":"10","author":[{"given":"Hayder M.","family":"Al-Kuraishy","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali I.","family":"Al-Gareeb","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali K.","family":"Al-Buhadily","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, Toxicology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2020,2,19]]},"reference":[{"key":"key-10.4103\/0974-2727.236108-1","first-page":"304","volume-title":"Abundance of antibiotics, antibiotic resistance genes and bacterial community composition in wastewater effluents from different Romanian hospitals","author":"Szekeres","year":"2017","journal-title":"Environ Pollut"},{"key":"key-10.4103\/0974-2727.236108-2","first-page":"982","volume-title":"Drug-resistant gram-negative uropathogens: A review","author":"Khoshnood","year":"2017","journal-title":"Biomed Pharmacother"},{"key":"key-10.4103\/0974-2727.236108-3","first-page":"751","volume-title":"Non-antibiotics reverse resistance of bacteria to antibiotics","author":"Kristiansen","year":"2010","journal-title":"In Vivo"},{"key":"key-10.4103\/0974-2727.236108-4","first-page":"198","volume-title":"Potential role of non-antibiotics (helper compounds) in the treatment of multidrug-resistant gram-negative infections: Mechanisms for their direct and indirect activities","author":"Martins","year":"2008","journal-title":"Int J Antimicrob Agents"},{"key":"key-10.4103\/0974-2727.236108-5","first-page":"8","volume-title":"Effects of Rosuvastatin alone or in combination with omega-3 fatty acid on adiponectin levels and cardio metabolic profile","author":"Al-Kuraishy","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"key-10.4103\/0974-2727.236108-6","first-page":"OC17","volume-title":"Sepsis mortality in critical care and prior statin therapy: A Retrospective cohort study in central Argentina","author":"Paricahua","year":"2017","journal-title":"J Clin Diagn Res"},{"key":"key-10.4103\/0974-2727.236108-7","first-page":"13","volume-title":"Antibacterial activity of statins: A comparative study of atorvastatin, simvastatin, and rosuvastatin","author":"Masadeh","year":"2012","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"key-10.4103\/0974-2727.236108-8","first-page":"321","volume-title":"Formulation and evaluation of cefixime trihydrate matrix tablets using HPMC, sodium CMC, ethyl cellulose","author":"Sirisolla","year":"2015","journal-title":"Indian J Pharm Sci","ISSN":"https:\/\/id.crossref.org\/issn\/0250-474X","issn-type":"print"},{"key":"key-10.4103\/0974-2727.236108-9","first-page":"71","volume-title":"Community-acquired methicillin-resistant Staphylococcus aureus carriage rate and antimicrobial susceptibility in a tertiary center, Iran","author":"Shokouhi","year":"2017","journal-title":"J Res Med Sci","ISSN":"https:\/\/id.crossref.org\/issn\/1735-1995","issn-type":"print"},{"key":"key-10.4103\/0974-2727.236108-10","first-page":"871","volume-title":"Antibiotic susceptibility and resistance testing: An overview","author":"Smaill","year":"2000","journal-title":"Can J Gastroenterol"},{"key":"key-10.4103\/0974-2727.236108-11","first-page":"321","volume-title":"Synergy against extensively drug-resistant Acinetobacter baumannii in vitro by two old antibiotics: Colistin and chloramphenicol","author":"Wei","year":"2017","journal-title":"Int J Antimicrob Agents"},{"key":"key-10.4103\/0974-2727.236108-12","doi-asserted-by":"crossref","unstructured":"Fratini F, Mancini S, Turchi B, Friscia E, Pistelli L, Giusti G, et al. Anovel interpretation of the fractional inhibitory concentration index: The case Origanum vulgare L. And Leptospermum scoparium J. R. et G. Forst essential oils against Staphylococcus aureus strains. Microbiol Res 2017;195:11-7.","DOI":"10.1016\/j.micres.2016.11.005"},{"key":"key-10.4103\/0974-2727.236108-13","first-page":"14","volume-title":"Therapeutic strategies to combat antibiotic resistance","author":"Brooks","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"key-10.4103\/0974-2727.236108-14","first-page":"144","volume-title":"Antibacterial activity and antibiotic modulating potential of the essential oil obtained from Eugenia jambolana in association with led lights","author":"Pereira","year":"2017","journal-title":"J Photochem Photobiol B"},{"key":"key-10.4103\/0974-2727.236108-15","first-page":"381","volume-title":"Experimental antibacterial activity of selective cyclooxygenase antagonist","author":"Al-Kuraishy","year":"2013","journal-title":"Int J Basic Clin Pharmacol"},{"key":"key-10.4103\/0974-2727.236108-16","first-page":"161","volume-title":"Investigation of the in vitro antibacterial effects of statins","author":"Coban","year":"2010","journal-title":"Mikrobiyol Bul"},{"key":"key-10.4103\/0974-2727.236108-17","first-page":"362","volume-title":"Unexpected antimicrobial effect of statins","author":"Jerwood","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"key-10.4103\/0974-2727.236108-18","first-page":"e0128098","volume-title":"Statins and antimicrobial effects: Simvastatin as a potential drug against Staphylococcus aureus biofilm","author":"Graziano","year":"2015","journal-title":"PLoS One"},{"key":"key-10.4103\/0974-2727.236108-19","first-page":"689","volume-title":"Antimicrobial action of atorvastatin and rosuvastatin","author":"Welsh","year":"2009","journal-title":"Pathology"},{"key":"key-10.4103\/0974-2727.236108-20","first-page":"7587","volume-title":"Antimicrobial activity of rosuvastatin","author":"Alagi\u0107-D\u017eambi\u0107","year":"2015","journal-title":"Int J Pharm Technol"},{"key":"key-10.4103\/0974-2727.236108-21","first-page":"e24394","volume-title":"Studies on the antibacterial effects of statins \u2013In vitro and in vivo","author":"Bergman","year":"2011","journal-title":"PLoS One"},{"key":"key-10.4103\/0974-2727.236108-22","first-page":"5766","volume-title":"Statins increase rifampin mycobactericidal effect","author":"Lobato","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"key-10.4103\/0974-2727.236108-23","first-page":"2453","volume-title":"Simvastatin increases the in vivo activity of the first-line tuberculosis regimen","author":"Skerry","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"key-10.4103\/0974-2727.236108-24","first-page":"1401","volume-title":"Biosynthesis of isoprenoids via the non-mevalonate pathway","author":"Eisenreich","year":"2004","journal-title":"Cell Mol Life Sci"},{"key":"key-10.4103\/0974-2727.236108-25","first-page":"1253","volume-title":"Cholesterol suppresses antimicrobial effect of statins","author":"Haeri","year":"2015","journal-title":"Iran J Basic Med Sci"},{"key":"key-10.4103\/0974-2727.236108-26","first-page":"107","volume-title":"Exploring of antimicrobial activity of Triphala Mashi-an ayurvedic formulation","author":"Biradar","year":"2008","journal-title":"Evid Based Complement Alternat Med"},{"key":"key-10.4103\/0974-2727.236108-27","first-page":"1760","volume-title":"Hydroxymethylglutaryl coenzyme A reductase inhibitors modify the inflammatory response of human macrophages and endothelial cells infected with Chlamydia pneumoniae","author":"Kothe","year":"2000","journal-title":"Circulation"},{"key":"key-10.4103\/0974-2727.236108-28","first-page":"3103","volume-title":"Hexagonal liquid crystalline nanodispersions proven superiority for enhanced oral delivery of rosuvastatin:In vitro characterization and in vivo pharmacokinetic study","author":"Gabr","year":"2017","journal-title":"J Pharm Sci"},{"key":"key-10.4103\/0974-2727.236108-29","first-page":"336","volume-title":"Effect of HMG-coA reductase inhibitors on antimicrobial susceptibilities for gram-negative rods","author":"Farmer","year":"2013","journal-title":"J Basic Microbiol"},{"key":"key-10.4103\/0974-2727.236108-30","first-page":"S1095","volume-title":"Synthesis and antibacterial activity of novel N-acylsulfonamides","author":"Berredjem","year":"2017","journal-title":"Arabian J Chem"},{"key":"key-10.4103\/0974-2727.236108-31","first-page":"347","volume-title":"Physicochemical regulation of biofilm formation","author":"Renner","year":"2011","journal-title":"MRS Bull"},{"key":"key-10.4103\/0974-2727.236108-32","first-page":"438","volume-title":"AQSAR-based mechanistic study on the combined toxicity of antibiotics and quorum sensing inhibitors against Escherichia coli","author":"Wang","year":"2018","journal-title":"JHazard Mater"},{"key":"key-10.4103\/0974-2727.236108-33","first-page":"5111","volume-title":"Is there potential for repurposing statins as novel antimicrobials?","author":"Hennessy","year":"2016","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Laboratory Physicians"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.4103\/JLP.JLP_170_17.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,24]],"date-time":"2023-12-24T08:15:27Z","timestamp":1703405727000},"score":1,"resource":{"primary":{"URL":"https:\/\/jlabphy.org\/rosuvastatin-as-forthcoming-antibiotic-or-as-adjuvant-additive-agent-in-vitro-novel-antibacterial-study\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":33,"journal-issue":{"issue":"03","published-online":{"date-parts":[[2020,2,19]]},"published-print":{"date-parts":[[2018,7]]}},"URL":"https:\/\/doi.org\/10.4103\/jlp.jlp_170_17","relation":{},"ISSN":["0974-2727","0974-7826"],"issn-type":[{"value":"0974-2727","type":"print"},{"value":"0974-7826","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}